IntegraGen is a French biotech company based on the Genopole life science park in Evry, near Paris. It leverages its unique intellectual property, research expertise and privileged access to sample libraries to develop molecular markers for central nervous system and metabolic diseases. IntegraGen notably uses its proprietary technology platforms to provide genomics services to the pharmaceutical industry, biotech firms and other research providers.

Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium and owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen. In 1961, Janssen Pharmaceutica was purchased by New Jersey-based American corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), now renamed to Janssen Research and Development (JRD), which conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anaesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been placed in the Ortho-McNeil-Janssen group within Johnson & Johnson Company.

Richter Gedeon Nyrt deals with pharmaceutical production, research and development, trade, and marketing.

Ovid is a pure play neurology company focused on rare and orphan diseases of the brain. They were founded in 2014 to leverage recent advances in science and medicine to find optimal therapies. They seek to identify and develop late stage, de-risked medicines with significant potential. Their rationale for developing these medicines is based on key insights from their scientific founders and confirmed in discussions with leading experts in the field. Their products are protected by strong intellectual property. They apply the most efficient processes to bring safe and effective therapies to patients. They are based in New York City but have collaborators and are working with patients across the United States and the globe.

Neuren Pharmaceuticals Limited is a biopharmaceutical company developing drugs for brain injury and neurodegeneration. The drugs target acute indications of brain injury such as traumatic brain injury, as well as chronic conditions such as Parkinson’s and Alzheimer’s diseases. Neuren is also engaged in research and development in metabolic disorders such as cancers related to the functions of growth hormone. Neuren has three lead candidates; Motiva™ and NNZ-2566 presently in clinical development to treat three different neurological conditions, and NNZ-2591 in preclinical development for Parkinson’s disease dementia and other chronic neurodegenerative conditions. Neuren has operations in New Zealand (Auckland based head office), Australia and the United States, and is listed on the Australian Securities Exchange (ASX: NEU).

Woolsey Pharmaceuticals is a pharmaceutical company that specializes in reinventing ways to treat some of the world’s most challenging diseases. The company's approach allows them to accelerate the delivery of medicines for the benefit of all humankind. The company was founded in 2019 and is headquartered in New York, United States.

Guangzhou Yiming Scientific Instrument Co., Ltd., established on 2003-09-28, Business scope includes wholesale of office equipment consumables;Manufacturing of special equipment for teaching;Medical Equipment Repair;Information Electronic Technology Services;Research and development of teaching equipment;software development;Commodity Information Consulting Service;Retailing of office equipment consumables;Manufacture of Mechanical Therapy and Ward Nursing Equipment;

Zhongke Weizhi (Beijing) Biotechnology Co., Ltd., established on 2021-11-04, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;software development;data processing services;Conference and Exhibition Services;Natural science research and experimental development;Engineering and Technology Research and Experimental Development;Agricultural Science Research and Experimental Development;Medical Research and Experimental Development;Non-residential real estate leases.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Drug Clinical Trial Services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)(Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. The company also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.

Beijing Tujian Technology Co., Ltd., established on 2019-02-26, Business scope includes software development;e-commerce,computer technology,network technology,Technology development in the field of communication technology,technology transfer,technical consulting,Technical Services;graphic design,make;design,make,Advertisement on behalf of cloth;selling computers,Software and Auxiliary Equipment,Class I Medical Device Class II;Business Management Consulting,buisness planning(No intermediary services);marketing;Agent import and export,Technology Import and Export,Import and export;computer system integration;product design.(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

Edison is a world leader in the discovery and development of redox drugs. The company has obtained orphan designation in both the United States and Europe for its first drug candidate, EPI-743 . Vincerinone is now in phase 2 clinical development. It is being evaluated in multiple clinical indications where defects in the mitochondrial proteins and redox control have been well characterized.

Cavion is a clinical stage pharmaceutical company committed to providing patients with therapies for cancer and neurologic diseases through the development of drugs that selectively inhibit the T-type calcium channel (Cav3). Built on the discovery by Cavion’s founders that ion channels are a target for the treatment of solid tumor cancers, they were the first company to invent therapies engaging Cav3 for the treatment of solid tumors. The innovative idea of treating pathologically proliferating, non-electrically excitable cells by targeting an ion channel has already shown success in preclinical studies and is being tested in Phase 1 safety and dose-finding clinical trials in brain cancer. Their technology is intended to magnify the effects of combined chemotherapy, radiation, and targeted therapies for all solid tumor cancers. Their neurology program uses superior chemistry and clinical expertise to deliver a novel class of drugs that will provide patients with treatments for neurologic diseases. While Cav3 is an established target in neurology, particularly neuropathic pain, Cavion is working to bring the first non-addictive, non-opioid T-type calcium channel antagonist to patients with neuropathic pain. Given that Cav3 plays a role in numerous pathologic conditions, Cavion is simultaneously developing therapies for additional neurologic afflictions such as essential tremor, Parkinson’s disease, epilepsy, and Angelman syndrome.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. It develops a platform bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The company was founded by Joseph P. Errico, Steven M. Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Rockaway, NJ.

Science & Technology Corp. provides scientific, technical, and engineering services. The firm Specializes in defense chemical and biological research, test and evaluation, range support services, earth and space sciences, polar technologies, aerospace engineering and information systems engineering and support. The company was founded in 1979 and is headquartered in Hampton, VA.

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

Part of Danone SA, SHS International Ltd. is a British company located in Liverpool. The firm manufactures homogenized food and dietetic food. It was founded in 1910.\nThe company says this about itself: The principal activity of the company is the research and development, manufacture and sale of special dietary products for the healthcare market. The healthcare products are primarily for the treatment of cows milk allergy and inborn errors of metabolism. The products are distributed worldwide and are available on prescription through healthcare systems in most countries.

Shenzhen Mind Psychometry Technology Research Institute Co., Ltd., established on 2016-05-04, Business scope includes general business items:Research and development of psychometric technology,Application and Training;Information Technology and System Services,Software technical service;Domestic Trade(Does not contain franchise,monopoly,Specially Controlled Commodities);Operating import and export business(law,Administrative regulations,Except for items prohibited by the State Council,Restricted projects must obtain a license before operating).,The licensing program is: